Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation

Clinical and Experimental Immunology

Volumn 148, Issue 3, 2007, Pages 520-528

  Clausen, J ^a   Wolf, D ^a   Petzer, A L ^a   Gunsilius, E ^a   Schumacher, P ^a   Kircher, B ^a   Gastl, G ^a   Nachbaur, D ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

KIR; Natural killer; NK cell; Stem cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; HUMAN CELL; INCIDENCE; LYMPHOCYTE COUNT; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; MYCOSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SIBLING; T LYMPHOCYTE; UNIVARIATE ANALYSIS;

ACUTE DISEASE; CHRONIC DISEASE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTIONS; RECEPTORS, IMMUNOLOGIC; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 34247853271     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03360.x     Document Type: Article

References (46)

1. Rocha V, Labopin M, Gluckman E et al. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol 2002 20:4324 30.
2. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001 98:3221 7.
3. Lee SH, Lee MH, Lee JH et al. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant 2005 11:122 8.
4. Cao TM, Shizuru JA, Wong RM et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005 105:2300 6.
5. Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003 31:839 45.
6. Gorin NC, Labopin M, Rocha V et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003 102:3043 51.
7. Singhal S, Powles R, Treleaven J et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 1 0(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000 26:489 96.
8. Perez-Simon JA, Diez-Campelo M, Martino R et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003 102:1108 13.
9. Diez-Campelo M, Perez-Simon J, Ocio E et al. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymph 2005 46:177 83.
10. Reisner Y, Martelli MF. Transplantation tolerance induced by 'mega dose' CD34+ cell transplants. Exp Hematol 2000 28:119 27.
11. Mohty M, Bilger K, Jourdan E et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003 17:869 75.
12. Mohr B, Koch R, Thiede C et al. CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2004 34:949 54.
13. Sohn SK, Kim JG, Kim DH et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003 31:967 72.
14. Mielcarek M, Martin PJ, Heimfeld S et al. CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Leuk Lymph 2004 45:27 34.
15. Ringden O, Barrett AJ, Zhang MJ et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003 121:874 85.
16. Barrett AJ, Ringden O, Zhang MJ et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000 95:3323 7.
17. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 295:2097 100.
18. Nguyen S, Dhedin N, Vernant JP et al. NK cell reconstitution after haploidentical hematopoietic stem cell transplants: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005 105:4135 42.
19. Passweg JR, Stern M, Koehl U et al. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005 35:637 43.
20. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005 105:2594 600.
21. Johnson BD, Dagher N, Stankowski WC et al. Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. Biol Blood Marrow Transplant 2001 7:589 95.
22. Schmitz N, Beksac M, Hasenclever D et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002 100:761 7.
23. Yamasaki S, Henzan H, Ohno Y et al. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant 2003 32:505 10.
24. Panse JP, Heimfeld S, Guthrie KA et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005 128:659 67.
25. Baron F, Maris MB, Storer BE et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005 19:822 8.
26. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986 319:675 8.
27. Bishara A, De Santis D, Witt CC et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004 63:204 11.
28. Giebel S, Locatelli F, Lamparelli T et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003 102:814 19.
29. Davies SM, Ruggieri L, DeFor T et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002 100:3825 7.
30. Hsu KC, Gooley T, Malkki M et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006 12:828 36.
31. Farag SS, Bacigalupo A, Eapen M et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006 12:876 84.
32. Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004 103:1521 6.
33. Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005 105:4878 84.
34. Gumperz JE, Valiante NM, Parham P et al. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 1996 183:1817 27.
35. Frohn C, Schlenke P, Kirchner H. The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology 1997 92:567 70.
36. Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol 2004 16:634 43.
37. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986 314:729 35.
38. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001 97:3390 400.
39. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus serpositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006 76:414 9.
40. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. Am J Stat Assoc 1958 2003 53:457 81.
41. Labopin M, Iacobelli S. Statistical guidelines for EBMT. EBMT News. Available at: http://www.ebmt.org/4Registry/stat_docs/1999/ OPMAN_StatGuidelines_oct2003.pdf.
42. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999 18:695 706.
43. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999 94:333 9.
44. Kroger N, Binder T, Zabelina T et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 2006 82:1024 30.
45. Cao TM, Wong RM, Sheehan K et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005 33:279 85.
46. Passweg JR, Meyer-Monard S, Gregor M et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002 30:267 71.